Loading clinical trials...
Loading clinical trials...
A Phase III Multicenter, Open-label Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma
Conditions
Interventions
Rituximab
CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)
+2 more
Start Date
July 1, 2008
Primary Completion Date
May 1, 2011
Completion Date
May 1, 2011
Last Updated
May 15, 2017
NCT06667687
NCT05623982
NCT03314974
NCT04586478
NCT05054257
NCT01746849
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions